Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating United Homes Group, Inc. for potential breaches of fiduciary duties by its board of directors in relation to a proposed take-private sale that would cash out shareholders at a significantly reduced price of $1.18 per share, representing over a 50% discount from the last trading price of $2.38 [1][2][3] Group 1: Investigation Details - The investigation focuses on whether the proposed sale price of $1.18 per share is unfairly low compared to the market value prior to the announcement [3] - United Homes Group announced its agreement to become a wholly owned subsidiary of Stanley Martin Homes, LLC on February 23, 2026, which triggered the investigation [2] Group 2: Shareholder Actions - Current shareholders of United Homes Group are encouraged to seek additional information and may have legal options available to them [2][4] - Bleichmar Fonti & Auld LLP operates on a contingency fee basis, meaning shareholders will not incur costs for court expenses or litigation [4] Group 3: Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, with a strong track record of recovering significant amounts for clients [5]

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until March 6, 2026, to request to lead the case in the lawsuit titled Lupia v. Fermi Inc., et al., pending in the U.S. District Court for the Southern District of New York [3][12]. - The complaint includes securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Sections 11 and 15 of the Securities Act of 1933 [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations state that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Performance - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the termination of the Advance in Aid of Construction Agreement by the First Tenant [7][12].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating Mister Car Wash, Inc. and its controlling stockholder, Leonard Green & Partners, L.P. (LGP), for potential breaches of fiduciary duties related to a proposed take-private sale at $7 per share, which may be considered unfair to public shareholders [1][3][11]. Group 1: Investigation Details - The investigation was prompted by Mister Car Wash's announcement on February 18, 2026, regarding its agreement to be acquired by LGP for $7.00 per share, which may represent an unfairly low price for shareholders [3]. - LGP, owning over 66% of Mister Car Wash's common stock, has significant control over corporate decisions, including mergers and sales, raising concerns about conflicts of interest [4]. - LGP has already used its majority shares to approve the take-private sale without seeking further votes from public shareholders, potentially incentivizing a low sale price [5][6]. Group 2: Legal Options for Shareholders - Current shareholders of Mister Car Wash are encouraged to seek additional information and may have legal options available to them [2][7]. - BFA Law operates on a contingency fee basis, meaning shareholders will not incur costs unless the firm secures a favorable outcome [7].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4]. Allegations of Misconduct - The lawsuit claims that CoreWeave misrepresented its ability to meet customer demand and concealed significant construction delays at its data centers, which led to investor losses [5][13]. Stock Performance and Impact - CoreWeave's stock experienced notable declines: - On October 30, 2025, the stock dropped $8.87 (over 6%) after the merger with Core Scientific was terminated due to insufficient shareholder votes, falling from $139.93 to $131.06 [6]. - On November 11, 2025, the stock fell $17.22 (over 16%) after CoreWeave lowered its guidance for revenue and other metrics due to construction delays, dropping from $105.61 to $88.39 [7]. - On December 16, 2025, the stock decreased by $2.85 (over 3%) following reports of further delays in a major data center project, falling from $72.35 to $69.50 [8]. Legal Proceedings - Investors have until March 13, 2026, to request to lead the case in the U.S. District Court for the District of New Jersey, under the caption Masaitis v. CoreWeave, Inc., et al. [3][13].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3][10]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its accounts receivable collection practices, claiming to rely on "detailed reviews of historical collections," while actually using a 180-day cliff method for reserving uncollectable accounts [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses, constituting a violation of federal securities laws [4]. Group 3: Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and increased its professional liability reserves by $54 million, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 on November 13, 2025 [5][10].

Consolidated EBITDA increased 14% to $312.0 million versus $273.9 million a year earlier. Operating cash flow was $178.6 million, though the company emphasized reported operating cash flow was negatively impacted by Leadership Compensation Plan (LCP) distributions. Mendelson said approximately $22.7 million in distributions were made during the quarter to a long-tenured participant, and the company expects another distribution of about $73 million later in fiscal 2026. He said the LCP is fully funded via in ...

Strategic healthcare assets: A diversified set of investments that Raifeld said is currently valued at over $600 million , with recent momentum driven in part by clinical progress at Armata.Innoviva Specialty Therapeutics (IST): A commercial-stage critical care infectious disease platform. Raifeld said IST delivered almost $120 million in U.S. sales last year and that the company expects at least $150 million this year. He also pointed to a “best quarter ever” with $34 million in U.S. sales, describing it a ...

Selling, general, and administrative expenses increased to $34.7 million from $32.1 million, driven primarily by higher performance-based compensation accruals in the fourth quarter, along with $1.5 million of additional advertising and $1.6 million related to accelerated depreciation and write-off tied to the company’s legacy ERP system. Those costs were partially offset by restructuring actions taken in the second quarter, according to the CFO.Gross profit rose 8% year over year to $60.2 million, and gros ...

Management attributed the multi-year improvement in loss performance to both legislative reform and underwriting discipline. Harmsworth said claims and litigation frequency have declined for the past three years, producing a lower loss ratio in each successive year. He also said the combined ratio was under 45% in the fourth quarter, though he cautioned the figure was affected by “noise” related to Citizens assumptions completed during the quarter. On a normalized basis, he said the combined ratio was less ...

On Feb. 10, the Hawaii Supreme Court affirmed the lower court’s denial of subrogation insurers’ motion to intervene in the class settlement process. Seu said the decision “ends the insurer’s efforts to derail the class settlement” and “moves us one step closer toward final court approval of the settlement agreements.”On the settlement process, Seu said the company is working through remaining contingencies to payment and characterized the effort as being in the “home stretch,” with the “only remaining steps ...